Ianalumab Biosimilar Monoclonal Antibody (BAFF-R) for Research
Pre-Made Ianalumab biosimilar, Whole mAb, Anti-TNFRSF13C Antibody: Anti-BAFF-R/BAFFR/BROMIX/CD268/CVID4/prolixin therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ianalumab (INN; development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-256-1mg | 1mg | 618 |
Size: 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Ianalumab biosimilar, Whole mAb, Anti-TNFRSF13C Antibody: Anti-BAFF-R/BAFFR/BROMIX/CD268/CVID4/prolixin therapeutic antibody |
| INN Name | Ianalumab |
| Target | TNFRSF13C |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | H. Lee Moffitt Cancer Center and Research Institute;MorphoSys;Novartis |
| Conditions Approved | na |
| Conditions Active | Autoimmune hepatitis;Idiopathic pulmonary fibrosis;Multiple sclerosis;Pemphigus vulgaris;Rheumatoid arthritis;Sjogren's syndrome;Systemic lupus erythematosus;Chronic lymphocytic leukaemia |
| Conditions Discontinued | na |
| Development Tech | POTELLIGENT Technology |
About target - TNFRSF13C
1. Protein Tumor necrosis factor receptor superfamily member 13C
2. Gene TNFRSF13C
3. Organism Homo sapiens (Human)
Function
B-cell receptor specific for TNFSF13B/TALL1/BAFF/BLyS. Promotes the survival of mature B-cells and the B-cell response.

